|
1
|
Kim J, Harper A, McCormack V, Sung H,
Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I and
Fidler-Benaoudia MM: Global patterns and trends in breast cancer
incidence and mortality across 185 countries. Nat Med.
31:1154–1162. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou L and Yu CW: Epigenetic modulations
in triple-negative breast cancer: Therapeutic implications for
tumor microenvironment. Pharmacol Res. 204:1072052024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumari L, Mishra L, Patel P, Sharma N,
Gupta GD and Kurmi BD: Emerging targeted therapeutic strategies for
the treatment of triple-negative breast cancer. J Drug Target.
31:889–907. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiong N, Wu H and Yu Z: Advancements and
challenges in triple-negative breast cancer: A comprehensive review
of therapeutic and diagnostic strategies. Front Oncol.
14:14054912024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asleh K, Riaz N and Nielsen TO:
Heterogeneity of triple negative breast cancer: Current advances in
subtyping and treatment implications. J Exp Clin Cancer Res.
41:2652022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng X, Ma H, Wang J, Huang M, Fu D, Qin
L and Yin Q: Energy metabolism pathways in breast cancer
progression: The reprogramming, crosstalk, and potential
therapeutic targets. Transl Oncol. 26:1015342022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao
Y, Wang Q, Li Y, Hu F and Ren H: Metabolic reprogramming and
therapeutic resistance in primary and metastatic breast cancer. Mol
Cancer. 23:2612024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Warburg O, Posener K and Negelein E: The
metabolism of cancer cells. Biochem Z. 152:319–344. 1924.
|
|
9
|
Monzel AS, Enriquez JA and Picard M:
Multifaceted mitochondria: Moving mitochondrial science beyond
function and dysfunction. Nat Metab. 5:546–562. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan DC: Mitochondrial dynamics and its
involvement in disease. Annu Rev Pathol. 15:235–259. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Picard M and Shirihai OS: Mitochondrial
signal transduction. Cell Metab. 34:1620–1653. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ashrafi G and Schwarz TL: The pathways of
mitophagy for quality control and clearance of mitochondria. Cell
Death Differ. 20:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Lu S, Wu LL, Yang L, Yang L and
Wang J: The diversified role of mitochondria in ferroptosis in
cancer. Cell Death Dis. 14:5192023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Y, Li Z, Zhang S, Zhang T, Liu Y and
Zhang L: Cellular mitophagy: Mechanism, roles in diseases and small
molecule pharmacological regulation. Theranostics. 13:736–766.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim J, Fiesel FC, Belmonte KC, Hudec R,
Wang WX, Kim C, Nelson PT, Springer W and Kim J: miR-27a and
miR-27b regulate autophagic clearance of damaged mitochondria by
targeting PTEN-induced putative kinase 1 (PINK1). Mol Neurodegener.
11:552016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trempe JF and Gehring K: Structural
mechanisms of mitochondrial quality control mediated by PINK1 and
Parkin. J Mol Biol. 435:1680902023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai K, Radin DP and Leonardi D:
Deciphering the dual role and prognostic potential of PINK1 across
cancer types. Neural Regen Res. 16:659–665. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goncalves FB and Morais VA: PINK1: A
bridge between mitochondria and Parkinson's disease. Life (Basel).
11:3712021.PubMed/NCBI
|
|
19
|
Wang M, Luan S, Fan X, Wang J, Huang J,
Gao X and Han D: The emerging multifaceted role of PINK1 in cancer
biology. Cancer Sci. 113:4037–4047. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Xu X, Huang H, Li L, Chen J, Ding Y
and Ping J: Pink1 promotes cell proliferation and affects
glycolysis in breast cancer. Exp Biol Med (Maywood). 247:985–995.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi C, de Wit S, Učambarlić E,
Markousis-Mavrogenis G, Screever EM, Meijers WC, de Boer RA and
Aboumsallem JP: Multifactorial diseases of the heart, kidneys,
lungs, and liver and incident cancer: Epidemiology and shared
mechanisms. Cancers (Basel). 15:7292023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu D, Li Y, Niu X, Sun J, Zhan W, Shi Y,
Yu K, Huang S, Liu X, Xie L, et al: STAT2/SLC27A3/PINK1-mediated
mitophagy remodeling lipid metabolism contributes to pazopanib
resistance in clear cell renal cell carcinoma. Research (Wash DC).
7:05392024.PubMed/NCBI
|
|
23
|
Li YQ, Zhang F, Yu LP, Mu JK, Yang YQ, Yu
J and Yang XX: Targeting PINK1 using natural products for the
treatment of human diseases. Biomed Res Int. 2021:40458192021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin X, Xue R, Wu J, Wu M, Xie B and Meng
Q: PINK1 ameliorates acute-on-chronic liver failure by inhibiting
apoptosis through mTORC2/AKT signaling. Cell Death Discov.
8:2222022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo J and Chiang WC: Mitophagy in aging
and longevity. IUBMB Life. 74:296–316. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Gaetano A, Gibellini L, Zanini G, Nasi
M, Cossarizza A and Pinti M: Mitophagy and oxidative stress: The
role of aging. Antioxidants (Basel). 10:7942021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deepak K, Roy PK, Das CK, Mukherjee B and
Mandal M: Mitophagy at the crossroads of cancer development:
Exploring the role of mitophagy in tumor progression and therapy
resistance. Biochim Biophys Acta Mol Cell Res. 1871:1197522024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu K, Aoki C, Elste A, Rogalski-Wilk AA
and Siekevitz P: The synthesis of ATP by glycolytic enzymes in the
postsynaptic density and the effect of endogenously generated
nitric oxide. Proc Natl Acad Sci USA. 94:13273–13278. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vishwanatha JK, Jindal HK and Davis RG:
The role of primer recognition proteins in DNA replication:
Association with nuclear matrix in HeLa cells. J Cell Sci.
101:25–34. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Popanda O, Fox G and Thielmann HW:
Modulation of DNA polymerases alpha, delta and epsilon by lactate
dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta.
1397:102–117. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Semenza GL: Regulation of mammalian O2
homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol.
15:551–578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu XX, Zhang H, Shen XF, Liu FJ, Liu J
and Wang WJ: Characteristics of testis-specific phosphoglycerate
kinase 2 and its association with human sperm quality. Hum Reprod.
31:273–279. 2016.PubMed/NCBI
|
|
33
|
Chiarelli LR, Morera SM, Bianchi P, Fermo
E, Zanella A, Galizzi A and Valentini G: Molecular insights on
pathogenic effects of mutations causing phosphoglycerate kinase
deficiency. PLoS One. 7:e320652012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Danshina PV, Geyer CB, Dai Q, Goulding EH,
Willis WD, Kitto GB, McCarrey JR, Eddy EM and O'Brien DA:
Phosphoglycerate kinase 2 (PGK2) is essential for sperm function
and male fertility in mice. Biol Reprod. 82:136–145. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rohozinski J, Anderson ML, Broaddus RE,
Edwards CL and Bishop CE: Spermatogenesis associated retrogenes are
expressed in the human ovary and ovarian cancers. PLoS One.
4:e50642009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu ST, Liu B, Ai ZZ, Hong ZC, You PT, Wu
HZ and Yang YF: Esculetin inhibits cancer cell glycolysis by
binding tumor PGK2, GPD2, and GPI. Front Pharmacol. 11:3792020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lingle W, Erickson BJ, Zuley ML, Jarosz R,
Bonaccio E, Filippini J, Net JM, Levi L, Morris EA, Figler GG, et
al: The cancer genome atlas breast invasive carcinoma collection
(TCGA-BRCA). The Cancer Imaging Archive; 2016
|
|
38
|
Hutter C and Zenklusen JC: The cancer
genome atlas: Creating lasting value beyond its data. Cell.
173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ogata H, Goto S, Fujibuchi W and Kanehisa
M: Computation with the KEGG pathway database. Biosystems.
47:119–128. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liberzon A, Birger C, Thorvaldsdottir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong W, Kuang M, Chen H, Luo Y, You K,
Zhang B and Liu Y: Single-sample gene set enrichment analysis
reveals the clinical implications of immune-related genes in
ovarian cancer. Front Mol Biosci. 11:14262742024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rosner B, Glynn RJ and Lee MLT:
Incorporation of clustering effects for the Wilcoxon rank sum test:
A large-sample approach. Biometrics. 59:1089–1098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Canzler S and Hackermüller J: multiGSEA: A
GSEA-based pathway enrichment analysis for multi-omics data. BMC
Bioinformatics. 21:5612020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Love M, Anders S and Huber W: Differential
analysis of count data-the DESeq2 package. Genome Biol. 15:10–1186.
2014.
|
|
45
|
Kolde R and Kolde MR: Package ‘pheatmap’.
R Package. 1:7902015.
|
|
46
|
Yuan F, Pan X, Chen L, Zhang YH, Huang T
and Cai YD: Analysis of protein-protein functional associations by
using gene ontology and KEGG pathway. Biomed Res Int.
2019:49632892019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sedgwick P: Spearman's rank correlation
coefficient. BMJ. 349:g73272014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Therneau TM and Lumley T: Package
‘survival’. R Top Doc. 128:28–33. 2015.
|
|
50
|
Santos P, Rezende CP, Piraine R, Oliveira
B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M and Almeida F:
Extracellular vesicles from human breast cancer-resistant cells
promote acquired drug resistance and pro-inflammatory macrophage
response. Front Immunol. 15:14682292024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Onishi M, Yamano K, Sato M, Matsuda N and
Okamoto K: Molecular mechanisms and physiological functions of
mitophagy. EMBO J. 40:e1047052021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pickles S, Vigié P and Youle RJ: Mitophagy
and quality control mechanisms in mitochondrial maintenance. Curr
Biol. 28:R170–R185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kerneur C, Cano CE and Olive D: Major
pathways involved in macrophage polarization in cancer. Front
Immunol. 13:10269542022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S,
Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu
YP, Acevedo-Arozena A, et al: Guidelines for the use and
interpretation of assays for monitoring autophagy (4th
edition)1. Autophagy. 17:1–382. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bertolin G, Ferrando-Miguel R, Jacoupy M,
Traver S, Grenier K, Greene AW, Dauphin A, Waharte F, Bayot A,
Salamero J, et al: The TOMM machinery is a molecular switch in
PINK1 and PARK2/PARKIN-dependent mitochondrial clearance.
Autophagy. 9:1801–1817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Requejo-Aguilar R, Lopez-Fabuel I,
Fernandez E, Martins LM, Almeida A and Bolaños JP: PINK1 deficiency
sustains cell proliferation by reprogramming glucose metabolism
through HIF1. Nat Commun. 5:45142014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fahad Ullah M: Breast cancer: Current
perspectives on the disease status. Adv Exp Med Biol. 1152:51–64.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Faubert B, Solmonson A and DeBerardinis
RJ: Metabolic reprogramming and cancer progression. Science.
368:eaaw54732020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lin HY and Chu PY: Advances in
understanding mitochondrial MicroRNAs (mitomiRs) on the
pathogenesis of triple-negative breast cancer (TNBC). Oxid Med Cell
Longev. 2021:55177772021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chu CT: A pivotal role for PINK1 and
autophagy in mitochondrial quality control: Implications for
Parkinson disease. Hum Mol Genet. 19:R28–R37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chang G, Zhang W, Ma Y and Wen Q: PINK1
expression is associated with poor prognosis in lung
adenocarcinoma. Tohoku J Exp Med. 245:115–121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Alizadeh J, Kavoosi M, Singh N, Lorzadeh
S, Ravandi A, Kidane B, Ahmed N, Mraiche F, Mowat MR and Ghavami S:
Regulation of autophagy via carbohydrate and lipid metabolism in
cancer. Cancers (Basel). 15:21952023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Rojas-Pirela M, Andrade-Alviárez D, Rojas
V, Kemmerling U, Cáceres AJ, Michels PA, Concepción JL and Quiñones
W: Phosphoglycerate kinase: Structural aspects and functions, with
special emphasis on the enzyme from Kinetoplastea. Open Biol.
10:2003022020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Brito-Arias M: Enzymes involved in
glycolysis, fatty acid and amino acid biosynthesis: Active site
mechanism and inhibition. Bentham Science Publishers; 2020,
View Article : Google Scholar
|
|
66
|
Yin K, Lee J, Liu Z, Kim H, Martin DR, Wu
D, Liu M and Xue X: Mitophagy protein PINK1 suppresses colon tumor
growth by metabolic reprogramming via p53 activation and reducing
acetyl-CoA production. Cell Death Differ. 28:2421–2435. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Icard P, Wu Z, Fournel L, Coquerel A,
Lincet H and Alifano M: ATP citrate lyase: A central metabolic
enzyme in cancer. Cancer Lett. 471:125–134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kierans SJ and Taylor CT: Regulation of
glycolysis by the hypoxia-inducible factor (HIF): Implications for
cellular physiology. J Physiol. 599:23–37. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kung-Chun Chiu D, Pui-Wah Tse A, Law CT,
Ming-Jing Xu I, Lee D, Chen M, Kit-Ho Lai R, Wai-Hin Yuen V,
Wing-Sum Cheu J, Wai-Hung Ho D, et al: Hypoxia regulates the
mitochondrial activity of hepatocellular carcinoma cells through
HIF/HEY1/PINK1 pathway. Cell Death Dis. 10:9342019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Maddocks OD and Vousden KH: Metabolic
regulation by p53. J Mol Med (Berl). 89:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen Y, Anwar M, Wang X, Zhang B and Ma B:
Integrative transcriptomic and single-cell analysis reveals IL27RA
as a key immune regulator and therapeutic indicator in breast
cancer. Discov Oncol. 16:9772025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li B, Lin R, Hua Y, Ma B and Chen Y:
Single-cell RNA sequencing reveals TMEM71 as an immunomodulatory
biomarker predicting immune checkpoint blockade response in breast
cancer. Discov Oncol. 16:12562025. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li K, Chen Y, Zhang Z, Wang K, Sulayman S,
Zeng X, Ababaike S, Guan J and Zhao Z: Preoperative
pan-immuno-inflammatory values and albumin-to-globulin ratio
predict the prognosis of stage I–III colorectal cancer. Sci Rep.
15:115172025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zeng X, Wu Z, Pan Y, Ma Y, Chen Y and Zhao
Z: Effects of micronutrients and macronutrients on risk of allergic
disease in the European population: A Mendelian randomization
study. Food Agric Immunol. 35:24423692024. View Article : Google Scholar
|
